Skip to content
Medical Health Aged Care

Overdose report shows more needs to be done

Pharmaceutical Society of Australia (PSA) 2 mins read

The Pharmaceutical Society of Australia (PSA) is calling for governments, health workers and support organisations to work together to do more to tackle the ongoing challenge of deaths caused by intentional and unintentional drug overdose. 

The Penington Institute’s Annual Overdose Report, released today, found there were 544 unintentional drug-induced deaths in Australia in 2021. Opioids and benzodiazepines were among the most common drugs involved in accidental overdose deaths.  

The report showed more than two-thirds of all unintentional drug-induced deaths involved two or more drug types (72.5%), with presence of benzodiazepines (such as diazepam, lorazepam and alprazolam) increasingly implicated in unintentional drug-induced deaths.  Anti-depressants (38%), stimulants (35%), and alcohol (25%) were also observed in unintentional deaths with two or more drug types.  

PSA National President Dr Fei Sim FPS said the report was a sobering reminder of the work still to be done to prevent avoidable harm from drug, including prescription medicines.  

“More Australians are using more medicines than ever before, and prescribing of multiple medicines to manage health conditions is increasingly common,” Dr Sim said. “However, some drug-drug combinations dramatically increase risk of unintentional drug-related death or hospitalisation, as this data tragically shows. 

“Real Time Prescription Monitoring is now available and must be used by health professionals to have non-judgemental conversations with people about the potential risks associated with medicines – and particularly when multiple medicines are being used at the same time. RTPM is making an impact but is not the whole answer. More solutions are needed. 

“As health professionals, we need to expand the way we assess risk. We need to recognise that medicine sharing happens and should form a routine part of all patient conversations about risk.  

“We need to offer Take Home Naloxone routinely and repeatedly to any person at-risk of experiencing or witnessing opioid overdose, and to people taking other medicines in combination with prescribed or illicit opioids.” 

Dr Sim called for more support for our health workforce to have conversations with potentially at-risk individuals in a meaningful, non-judgemental and supportive way, including by increasing access to training, guidelines, peer support and fostering collaboration of health teams. 

“Pharmacists work with at-risk individuals every day, but need better funding and support to be able to make a meaningful impact in reducing death and injury which drug overdose can cause. This includes building workforce capacity to be more active in deprescribing roles, particularly in primary care,” she said. 

“Pharmacists are the custodians of safe use of medicines, we are the key to reducing medicine-related harm. Pharmacists should be empowered and supported to do more to prevent medicine-related harm.   

“Every unintentional medicine-related harm is a failure of our health system. There is clearly more work to be done. I commend the Pennington Institute for producing this annual report, and for its impact over the previous eight years.” 

 

Media contact:   Dave Westman   M: 0402 411 984      E: [email protected]

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s 36,000 pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

Follow us on socials:      Facebook     Twitter      LinkedIn     Instagram

More from this category

  • Emergency Services, Medical Health Aged Care
  • 22/05/2025
  • 12:10
Charles Darwin University

Keep calm and carry on: Can Australian nurses really be ready for anything?

Australian nurses have responded to hundreds of disaster events over the last six years, but new research led by Charles Darwin University (CDU) suggests…

  • Contains:
  • Medical Health Aged Care
  • 22/05/2025
  • 10:12
Dementia Australia

Drug approval promising step for people with early Alzheimer’s disease

Dementia Australia welcomes the Therapeutic Goods Administration (TGA) registration of Kisunla (donanemab), for use in Australia, providing hope for people in the early stages of Alzheimer’s disease in the emerging treatments that may delay the progression of symptoms. Dementia Australia CEO Professor Tanya Buchanan said this drug was an exciting new development and another step forward in the treatment of Alzheimer’s disease. “With dementia the second leading cause of death of Australians, and the leading cause of death of Australian women, we welcome any steps taken towards improving the lives of people living with dementia, their families and carers,” Professor…

  • Contains:
  • Books Literature, Medical Health Aged Care
  • 22/05/2025
  • 09:40
Camilla Thompson / Wiley Publishing

Camilla Thompson unlocks the secrets of everyday biohacking for a longer, healthier life with new book: Biohack Me

What if you could supercharge your body, sharpen your mind, and future-proof your health, starting today? In her groundbreaking new book, Biohack Me, leadingbiohacker…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.